Fingerprint
Dive into the research topics of 'Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia
Henriette Huber, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Can Zhang, Eugen Tausch, Christof Schneider, Johannes Bloehdorn, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Durig, Sebastian Böttcher, Carsten Utoft Niemann, Michael Kneba, Anna Maria Fink, Kirsten Fischer, Hartmut Döhner